VIVAYZIO® is the first and only selective wake-transition receptor modulator (SWTRM) approved for CSIS.
VIVAYZIO® (somniclarin sodium) is a first-in-class selective wake-transition receptor modulator (SWTRM) that targets the cortical arousal pathway during the final phase of the sleep cycle.
During normal sleep architecture, the transition from Stage N2/N3 to wakefulness involves a coordinated cascade of neurotransmitter activity across the reticular activating system. In patients with CSIS, this cascade is delayed or incomplete, resulting in prolonged hypoarousal upon waking.
Vivayzio binds selectively to orexin-adjacent modulatory receptors (OAMRs) in the hypothalamus, priming the wake-transition cascade approximately 15–30 minutes before the patient's natural circadian wake signal. This results in a smoother, faster transition to full cortical arousal without the jittery overstimulation associated with traditional stimulant therapies.
Deep sleep phase with minimal cortical activity
Selective OAMR activation begins wake-preparation cascade
Coordinated dopamine, norepinephrine, and acetylcholine activation
Smooth transition to full wakefulness and alertness
| Vivayzio | Traditional Stimulants | Caffeine | |
|---|---|---|---|
| Mechanism | SWTRM (wake-transition) | CNS stimulant | Adenosine antagonist |
| Onset | Pre-wake priming | Post-wake activation | Post-wake, 20–45 min |
| Habit-forming | No | Yes (Schedule II–IV) | Mild physical dependence |
| Sleep disruption | None observed | Common | Dose-dependent |
| Targeted to CSIS | Yes | No | No |
Unlike broad-spectrum stimulants, VIVAYZIO specifically addresses the neurobiological deficit underlying CSIS without affecting other brain systems.
By working during sleep rather than after waking, VIVAYZIO prepares the brain for a natural, smooth transition to alertness.
Works with your body's natural rhythms rather than overriding them, preserving healthy sleep architecture.
Taken orally, once daily at bedtime
Take VIVAYZIO approximately 8 hours before your desired wake time. The medication works during your sleep cycle to prepare your brain for awakening.
Rapidly absorbed; Tmax = 2.5 hours
Crosses blood-brain barrier; Vd = 4.2 L/kg
Hepatic via CYP2D6 and CYP3A4
T1/2 = 6.8 hours; primarily renal
VIVAYZIO demonstrates high selectivity for orexin-adjacent modulatory receptors (OAMRs) with minimal off-target activity.
Begin with 7.5 mg dose. Some patients notice subtle improvements in wake quality by day 3-5.
Increase to full 15 mg dose. Most patients begin experiencing noticeable improvements in morning alertness.
Full therapeutic effects typically achieved. Consistent improvement in wake-onset cognitive delay scores.
Maintained efficacy with continued treatment. Quality of life improvements become well-established.
Remember: Individual results may vary. Some patients may experience benefits earlier, while others may need up to 12 weeks to achieve optimal results. Stay in close communication with your healthcare provider throughout your treatment journey.
Review the comprehensive clinical data from the SUNRISE trial program demonstrating VIVAYZIO's efficacy and safety.
View Clinical DataUnderstand the complete safety profile, contraindications, and important considerations before starting VIVAYZIO.
Important Safety InformationExplore patient support programs and savings options to help make VIVAYZIO accessible and affordable.
Get Support